Introduction Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and irreversible
lung disease. Licensed treatment options for IPF are pirfenidone and nintedanib. The aim of …

Background Pirfenidone and nintedanib are the only disease-modifying treatments available
for idiopathic pulmonary fibrosis (IPF). Our aim was to test their effectiveness and safety in …

Introduction Idiopathic pulmonary fibrosis (IPF) is a severe interstitial lung disease for which
two effective antifibrotics, nintedanib and pirfenidone, are available. However, many patients …

Background Real-life data on the use of pirfenidone and nintedanib to treat patients with
idiopathic pulmonary fibrosis (IPF) are still scarce. Methods We compared the efficacy of …

Abstract Background Research questions To compare the efficacy of nintedanib and
pirfenidone in the treatment of progressive pulmonary fibrosis; and to compare the efficacy of …

Background and objective Antifibrotic therapy with nintedanib or pirfenidone slows disease
progression and reduces mortality in patients with idiopathic pulmonary fibrosis (IPF) …

Extract The antifibrotic medications pirfenidone and nintedanib became the first US Food
and Drug Administration (FDA)-approved medical therapy for the treatment of idiopathic …

Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease with high mortality.
Two novel antifibrotic agents, pirfenidone and nintedanib, have received licences for use in …

Aim: Treatment either with nintedanib (N) or pirfenidone (P) can slow progression of
idiopathic pulmonary fibrosis (IPF). Long term effect of this treatment in the real world has not …

Background Idiopathic pulmonary fibrosis (IPF) is a chronic, fibrosing interstitial pneumonia
of unknown cause that is associated with radiological and/or histological features of usual …